In the Know About Recurrence, Sarah Adams, MD
-
Upload
ovarian-cancer-research-fund-alliance -
Category
Health & Medicine
-
view
1.002 -
download
3
Transcript of In the Know About Recurrence, Sarah Adams, MD
![Page 1: In the Know About Recurrence, Sarah Adams, MD](https://reader030.fdocuments.us/reader030/viewer/2022020119/5a6591dd7f8b9ac2368b45eb/html5/thumbnails/1.jpg)
Recurrent Ovarian Cancer Ovarian Cancer National Alliance Conference
Sarah Adams, MD July 25, 2015
![Page 2: In the Know About Recurrence, Sarah Adams, MD](https://reader030.fdocuments.us/reader030/viewer/2022020119/5a6591dd7f8b9ac2368b45eb/html5/thumbnails/2.jpg)
Outline
1. What are the chances that ovarian cancer will return after initial treatment?
2. What symptoms might suggest recurrent disease?
3. How is a recurrence diagnosed or confirmed?
4. *What treatment options are available and what factors affect decisions about which to choose?
5. *Are there benefits to enrolling in a clinical trial?
![Page 3: In the Know About Recurrence, Sarah Adams, MD](https://reader030.fdocuments.us/reader030/viewer/2022020119/5a6591dd7f8b9ac2368b45eb/html5/thumbnails/3.jpg)
Ovarian cancer subtypes
Most ovarian cancers arise from the lining of the ovary –the epithelial layer. Cancers arising from germ cells (eggs) or stromal cells are less common. In this presentation, I will focus on data about epithelial cancers (EOC).
![Page 4: In the Know About Recurrence, Sarah Adams, MD](https://reader030.fdocuments.us/reader030/viewer/2022020119/5a6591dd7f8b9ac2368b45eb/html5/thumbnails/4.jpg)
Ovarian cancer subtypes
Most ovarian cancers arise from the lining of the ovary –the epithelial layer. Cancers arising from germ cells (eggs) or stromal cells are less common. In this presentation, I will focus on data about epithelial cancers (EOC).
![Page 5: In the Know About Recurrence, Sarah Adams, MD](https://reader030.fdocuments.us/reader030/viewer/2022020119/5a6591dd7f8b9ac2368b45eb/html5/thumbnails/5.jpg)
Initial treatment: curative intent
Primary treatment: – Debulking or cytoreductive surgery
– Chemotherapy
• Neo-adjuvant chemotherapy (chemotherapy before surgery)
• Primary adjuvant chemotherapy (chemotherapy after surgery)
![Page 6: In the Know About Recurrence, Sarah Adams, MD](https://reader030.fdocuments.us/reader030/viewer/2022020119/5a6591dd7f8b9ac2368b45eb/html5/thumbnails/6.jpg)
Initial treatment: curative intent
Primary treatment: – Debulking or cytoreductive surgery
– Chemotherapy
• Neo-adjuvant chemotherapy (chemotherapy before surgery)
• Primary adjuvant chemotherapy (chemotherapy after surgery)
[Maintenance therapy: ongoing chemotherapy to reduce the risk of recurrence]
![Page 7: In the Know About Recurrence, Sarah Adams, MD](https://reader030.fdocuments.us/reader030/viewer/2022020119/5a6591dd7f8b9ac2368b45eb/html5/thumbnails/7.jpg)
Initial treatment: curative intent
Primary treatment: – Debulking or cytoreductive surgery
– Chemotherapy
• Neo-adjuvant chemotherapy (chemotherapy before surgery)
• Primary adjuvant chemotherapy (chemotherapy after surgery)
[Maintenance therapy: ongoing chemotherapy to reduce the risk of recurrence]
Cancer surveillance: • 3-month intervals for two years • 4-month intervals for the third year • 6-month intervals for up to 10 years
![Page 8: In the Know About Recurrence, Sarah Adams, MD](https://reader030.fdocuments.us/reader030/viewer/2022020119/5a6591dd7f8b9ac2368b45eb/html5/thumbnails/8.jpg)
What are the chances that ovarian cancer will return after initial treatment?
![Page 9: In the Know About Recurrence, Sarah Adams, MD](https://reader030.fdocuments.us/reader030/viewer/2022020119/5a6591dd7f8b9ac2368b45eb/html5/thumbnails/9.jpg)
0% 10% 20% 30% 40% 50% 60% 70% 80% 90%
Approximate Percentage of Recurrence
Stage I Stage II Stage III (optimal) Stage III (suboptimal) Stage IV
Ovarian cancer recurrence
![Page 10: In the Know About Recurrence, Sarah Adams, MD](https://reader030.fdocuments.us/reader030/viewer/2022020119/5a6591dd7f8b9ac2368b45eb/html5/thumbnails/10.jpg)
What symptoms might suggest recurrent disease?
![Page 11: In the Know About Recurrence, Sarah Adams, MD](https://reader030.fdocuments.us/reader030/viewer/2022020119/5a6591dd7f8b9ac2368b45eb/html5/thumbnails/11.jpg)
Symptoms associated with ovarian cancer recurrence
• Bloating, abdominal fullness, increased girth, indigestion • Pelvic pain • Change in bowel or bladder habits • Early satiety • Vaginal discharge or bleeding • Pain with intercourse • Lymphedema / leg swelling • Shortness of breath • Nausea, vomiting
*Any new or persistent symptoms should be reported to your oncologist
![Page 12: In the Know About Recurrence, Sarah Adams, MD](https://reader030.fdocuments.us/reader030/viewer/2022020119/5a6591dd7f8b9ac2368b45eb/html5/thumbnails/12.jpg)
How is a recurrence diagnosed or confirmed?
![Page 13: In the Know About Recurrence, Sarah Adams, MD](https://reader030.fdocuments.us/reader030/viewer/2022020119/5a6591dd7f8b9ac2368b45eb/html5/thumbnails/13.jpg)
Physical exam
• Physical exam – Evaluation of lymph nodes
– Chest exam for pleural fluid
– Abdominal exam for masses, fullness, fluid accumulation, pain
– Pelvic exam for masses or nodularity
– Extremities for swelling, tenderness, range of motion
• 35% who presented with symptoms had a normal physical exam
![Page 14: In the Know About Recurrence, Sarah Adams, MD](https://reader030.fdocuments.us/reader030/viewer/2022020119/5a6591dd7f8b9ac2368b45eb/html5/thumbnails/14.jpg)
CA125
• 61% of women diagnosed with recurrence based on an elevated CA125 level
– Rises in CA125 may precede symptomatic relapse by a median of 4.5
months (range 0.5-29.5 months)
– Doubling of CA125 has a sensitivity of 86% and a specificity of 91% for detecting progression.
– A second confirmatory value reduces the false-negative rate to <2%.
– Even a rise within the normal range is associated with a high risk of relapse.
![Page 15: In the Know About Recurrence, Sarah Adams, MD](https://reader030.fdocuments.us/reader030/viewer/2022020119/5a6591dd7f8b9ac2368b45eb/html5/thumbnails/15.jpg)
Imaging
• CT or MRI scan can be used to evaluate for recurrence – Imaging is indicated in response to new symptoms or a rise in CA125
– Sensitivity ranges from 40-93%
– It may be difficult to detect peritoneal or serosal disease
• PET sensitivity of 88-90%
• Directed biopsy may be performed to confirm recurrence
![Page 16: In the Know About Recurrence, Sarah Adams, MD](https://reader030.fdocuments.us/reader030/viewer/2022020119/5a6591dd7f8b9ac2368b45eb/html5/thumbnails/16.jpg)
What treatment options are available and what factors affect decisions about which to choose?
![Page 17: In the Know About Recurrence, Sarah Adams, MD](https://reader030.fdocuments.us/reader030/viewer/2022020119/5a6591dd7f8b9ac2368b45eb/html5/thumbnails/17.jpg)
Treatment goals for recurrent disease
• Recurrent ovarian cancer is unlikely to be cured with currently available chemotherapeutics, radiation or surgery.
Goal of treatment in the setting of recurrent disease is to prolong disease-free and overall survival and to palliate symptoms
• Options include surgery, chemotherapy, targeted therapeutics, immune therapy hormones, radiation, observation
![Page 18: In the Know About Recurrence, Sarah Adams, MD](https://reader030.fdocuments.us/reader030/viewer/2022020119/5a6591dd7f8b9ac2368b45eb/html5/thumbnails/18.jpg)
Surgery • Secondary (or tertiary) debulking surgery
– Rationale is based on benefit seen with primary debulking – Studies of secondary surgery are limited by patient selection Generally, surgery is reserved for women with:
• Platinum-sensitive disease • Limited sites of recurrence • Long treatment-free intervals (>24 mos) • Absence of ascites • Good performance status
• As with primary surgery, the best outcomes are seen in patients
who can be optimally debulked • Minimally invasive options (robotic or laparoscopic surgery) may
reduce morbidity for eligible women
![Page 19: In the Know About Recurrence, Sarah Adams, MD](https://reader030.fdocuments.us/reader030/viewer/2022020119/5a6591dd7f8b9ac2368b45eb/html5/thumbnails/19.jpg)
Chemotherapy
• Most patients respond to second-line chemotherapy
• Response to second-line chemotherapy is predicted by:
– Tumor type, size, and number of disease sites
– Duration of response to previous platinum based regimen, platinum-free interval and TFI (most important) • TFI <12 mos: Response Rate 24-35%
• TFI >12 mos: Response Rate 52-62%
![Page 20: In the Know About Recurrence, Sarah Adams, MD](https://reader030.fdocuments.us/reader030/viewer/2022020119/5a6591dd7f8b9ac2368b45eb/html5/thumbnails/20.jpg)
Platinum sensitivity
Most women with ovarian cancer receive a platinum drug (carboplatin, cisplatin, oxaloplatin) as part of their primary chemotherapy regimen.
The time to recurrence after platinum treatment determines “platinum
sensitivity”
Response to platinum
Likely secondary treatment
Examples
Platinum sensitive >6 months without recurrence
Another platinum-based regimen
Carboplatin alone or in combination with another drug
Platinum resistant < 6 months until recurrence
A non-platinum drug
Doxil, Taxol, Gemzar, Topotecan
Platinum refractory Failure to achieve remission
A non-platinum drug
Doxil, Taxol, Gemzar, Topotecan
![Page 21: In the Know About Recurrence, Sarah Adams, MD](https://reader030.fdocuments.us/reader030/viewer/2022020119/5a6591dd7f8b9ac2368b45eb/html5/thumbnails/21.jpg)
Platinum sensitivity
Most women with ovarian cancer receive a platinum drug (carboplatin, cisplatin, oxaloplatin) as part of their primary chemotherapy regimen.
The time to recurrence after platinum treatment determines “platinum
sensitivity”
Response to platinum
Likely secondary treatment
Examples
Platinum sensitive >6 months without recurrence
Another platinum-based regimen
Carboplatin, often in combination with another drug
Platinum resistant < 6 months until recurrence
A non-platinum drug
Doxil, Taxol, Gemzar, Topotecan
Platinum refractory Failure to achieve remission
A non-platinum drug
Doxil, Taxol, Gemzar, Topotecan
![Page 22: In the Know About Recurrence, Sarah Adams, MD](https://reader030.fdocuments.us/reader030/viewer/2022020119/5a6591dd7f8b9ac2368b45eb/html5/thumbnails/22.jpg)
Platinum sensitivity
Most women with ovarian cancer receive a platinum drug (carboplatin, cisplatin, oxaloplatin) as part of their primary chemotherapy regimen.
The time to recurrence after platinum treatment determines “platinum
sensitivity”
Response to platinum
Likely secondary treatment
Examples
Platinum sensitive >6 months without recurrence
Another platinum-based regimen
Carboplatin alone or in combination with another drug
Platinum resistant < 6 months until recurrence
A non-platinum drug
Doxil, Taxol, Gemzar, Topotecan
Platinum refractory Failure to achieve remission
A non-platinum drug
Doxil, Taxol, Gemzar, Topotecan
![Page 23: In the Know About Recurrence, Sarah Adams, MD](https://reader030.fdocuments.us/reader030/viewer/2022020119/5a6591dd7f8b9ac2368b45eb/html5/thumbnails/23.jpg)
Platinum sensitivity
Most women with ovarian cancer receive a platinum drug (carboplatin, cisplatin, oxaloplatin) as part of their primary chemotherapy regimen.
The time to recurrence after platinum treatment determines “platinum
sensitivity”
Response to platinum
Likely secondary treatment
Examples
Platinum sensitive >6 months without recurrence
Another platinum-based regimen
Carboplatin alone or in combination with another drug
Platinum resistant < 6 months until recurrence
A non-platinum drug
Doxil, Taxol, Gemzar, Topotecan
Platinum refractory Failure to achieve remission
A non-platinum drug
Doxil, Taxol, Gemzar, Topotecan
![Page 24: In the Know About Recurrence, Sarah Adams, MD](https://reader030.fdocuments.us/reader030/viewer/2022020119/5a6591dd7f8b9ac2368b45eb/html5/thumbnails/24.jpg)
Study (number of patients)
Agents Response Rate (%)
Progression free survival (months)
Overall survival (months)
ICON 4 (802) Carboplatin Carboplatin + Taxol
54% 66%
9 12*
24 29*
AGO (366) Carboplatin Carboplatin + Gemcitabine
31% 47%
5.8 8.6*
17.3 18
CALYPSO (976) Carboplatin + Taxol Carboplatin + Doxil
9.4 11.3*
31.5
OCEANS (484) Carboplatin + Gemcitabine Carbo+Gem+Avastin
57% 79%
8.4 12.4*
35.2 33.3
Clinical trials in platinum-sensitive patients with recurrent ovarian cancer
Coleman R, et al. Nat Rev Clin Oncol 5 Feb 2013
Response rates to second-line treatment are high among women with platinum –sensitive disease.
![Page 25: In the Know About Recurrence, Sarah Adams, MD](https://reader030.fdocuments.us/reader030/viewer/2022020119/5a6591dd7f8b9ac2368b45eb/html5/thumbnails/25.jpg)
Study (number of patients)
Agents Response Rate (%)
Progression free survival (months)
Overall survival (months)
ICON 4 (802) Carboplatin Carboplatin + Taxol
54% 66%
9 12*
24 29*
AGO (366) Carboplatin Carboplatin + Gemcitabine
31% 47%
5.8 8.6*
17.3 18
CALYPSO (976) Carboplatin + Taxol Carboplatin + Doxil
9.4 11.3*
31.5
OCEANS (484) Carboplatin + Gemcitabine Carbo+Gem+Avastin
57% 79%
8.4 12.4*
35.2 33.3
Clinical trials in platinum-sensitive patients with recurrent ovarian cancer
Coleman R, et al. Nat Rev Clin Oncol 5 Feb 2013
Platinum-sensitive patients are usually treated with another platinum-containing regimen – often carboplatin in combination with a second drug.
![Page 26: In the Know About Recurrence, Sarah Adams, MD](https://reader030.fdocuments.us/reader030/viewer/2022020119/5a6591dd7f8b9ac2368b45eb/html5/thumbnails/26.jpg)
Agent Response Rate (%)
Progression free survival (months)
Overall survival (months)
Side effects
Doxil 10-20% 3-4 10-12 Hand-foot syndrome, mucositis
Topotecan 12-18% 3-4 10-12 Myelosuppression
Taxotere 22% 3.5 12.7 Myelosuppression
Gemzar 15% 4-5 11.8-12.7 Myelosuppression
Etoposide 6-27% 4-5 10-11 Myelosuppression
Taxol 10-30% 4-6 13 Myelosuppression, neuropthy
Avastin 21% 4.7 17 Hypertension, blood clots
Most-frequently used agents in platinum-resistant disease
Coleman R, et al. Nat Rev Clin Oncol 5 Feb 2013
Because of the more limited prognosis associated with platinum-resistant disease, reducing toxicity becomes a primary goal, and typically single agent protocols are used.
![Page 27: In the Know About Recurrence, Sarah Adams, MD](https://reader030.fdocuments.us/reader030/viewer/2022020119/5a6591dd7f8b9ac2368b45eb/html5/thumbnails/27.jpg)
Targeted agents
• Advantages: – Different (often more limited) toxicity profile – May be active in chemotherapy resistant disease – Better understood mechanism of action
• Bevacizumab (Avastin): – blocks blood vessel formation in tumors – response rate greater than 20% (6 mo PFS 28-40%)
• PARP-inhibitors:
– block single-strand DNA repair – best response is among women with BRCA gene mutations – response rates as high as 33% in recurrent EOC
![Page 28: In the Know About Recurrence, Sarah Adams, MD](https://reader030.fdocuments.us/reader030/viewer/2022020119/5a6591dd7f8b9ac2368b45eb/html5/thumbnails/28.jpg)
Hormone therapy
• Advantages: – Lower toxicity
– Oral administration
• Tamoxifen: – Response rate of 17-20% among women with recurrent ovarian cancer
• Fulvestrant (selective estrogen receptor modulator) – Maintained disease stability in 50-64% of patients, 30% at 90 days
• Aromatase Inhibitors – Modest objective RR of 8-15%, stability in 19-24%
![Page 29: In the Know About Recurrence, Sarah Adams, MD](https://reader030.fdocuments.us/reader030/viewer/2022020119/5a6591dd7f8b9ac2368b45eb/html5/thumbnails/29.jpg)
Immune therapy
• Advantages: – Adaptive effects and potential for long-term benefit
– Toxicity profile is different than cytotoxic chemotherapy
• Currently available primarily through clinical trials
• Examples: – Cancer vaccines
– T cell therapy
– Immune checkpoint blockade antibodies
![Page 30: In the Know About Recurrence, Sarah Adams, MD](https://reader030.fdocuments.us/reader030/viewer/2022020119/5a6591dd7f8b9ac2368b45eb/html5/thumbnails/30.jpg)
Radiotherapy
• Whole abdominal radiation therapy is associated with significant toxicity and has limited efficacy in the treatment of recurrent disease
• Localized radiation may be effective – Good for symptom control
– Best for deposits in the pelvis, at the vaginal vault, on the abdominal wall.
– Median remission of 4.8 months.
![Page 31: In the Know About Recurrence, Sarah Adams, MD](https://reader030.fdocuments.us/reader030/viewer/2022020119/5a6591dd7f8b9ac2368b45eb/html5/thumbnails/31.jpg)
Observation -
When should treatment be initiated?
• Many oncologists believe that early diagnosis and treatment of recurrent disease improves outcomes for women with ovarian cancer – Better surgical outcomes – Smaller tumors are more susceptible to chemotherapeutics – Better symptom control
![Page 32: In the Know About Recurrence, Sarah Adams, MD](https://reader030.fdocuments.us/reader030/viewer/2022020119/5a6591dd7f8b9ac2368b45eb/html5/thumbnails/32.jpg)
Observation - When should treatment be initiated?
• Many oncologists believe that early diagnosis and treatment of recurrent disease improves outcomes for women with ovarian cancer – Better surgical outcomes – Smaller tumors are more susceptible to chemotherapeutics – Better symptom control
Rustin GJ,et al, Lancet 2010
• 2010 European study: Does earlier treatment improve survival?
![Page 33: In the Know About Recurrence, Sarah Adams, MD](https://reader030.fdocuments.us/reader030/viewer/2022020119/5a6591dd7f8b9ac2368b45eb/html5/thumbnails/33.jpg)
1442 women with ovarian cancer • complete remission • normal CA125 levels
• platinum-based primary chemotherapy.
Underwent CA125 testing every 3 months
529 experienced a doubling in CA125 and were randomized
265 assigned to the “early treatment” group • Clinicians and patients notified of the rise in
CA125 • Treatment initiated
264 assigned to “delayed treatment” group • Clinicians and patients blinded to CA125 levels • Treatment initiated when symptoms or clinical
findings suggested recurrence
Evaluated for the length of treatment-free intervals, overall survival, and quality of life
When should treatment be initiated?
2010 European study: Does earlier treatment improve survival?
Rustin GJ,et al, Lancet 2010
![Page 34: In the Know About Recurrence, Sarah Adams, MD](https://reader030.fdocuments.us/reader030/viewer/2022020119/5a6591dd7f8b9ac2368b45eb/html5/thumbnails/34.jpg)
1442 women with ovarian cancer • complete remission • normal CA125 levels
• platinum-based primary chemotherapy.
Underwent CA125 testing every 3 months
529 experienced a doubling in CA125 and were randomized
265 assigned to the “early treatment” group • Clinicians and patients notified of the rise in
CA125 • Treatment initiated
264 assigned to “delayed treatment” group • Clinicians and patients blinded to CA125 levels • Treatment initiated when symptoms or clinical
findings suggested recurrence
Evaluated for the length of treatment-free intervals, overall survival, and quality of life
When should treatment be initiated?
Rustin GJ,et al, Lancet 2010
2010 European study: Does earlier treatment improve survival?
![Page 35: In the Know About Recurrence, Sarah Adams, MD](https://reader030.fdocuments.us/reader030/viewer/2022020119/5a6591dd7f8b9ac2368b45eb/html5/thumbnails/35.jpg)
1442 women with ovarian cancer • complete remission • normal CA125 levels
• platinum-based primary chemotherapy.
Underwent CA125 testing every 3 months
529 experienced a doubling in CA125 and were randomized
265 assigned to the “early treatment” group • Clinicians and patients notified of the rise in
CA125 • Treatment initiated
264 assigned to “delayed treatment” group • Clinicians and patients blinded to CA125 levels • Treatment initiated when symptoms or clinical
findings suggested recurrence
Evaluated for the length of treatment-free intervals, overall survival, and quality of life
When should treatment be initiated?
Rustin GJ,et al, Lancet 2010
2010 European study: Does earlier treatment improve survival?
![Page 36: In the Know About Recurrence, Sarah Adams, MD](https://reader030.fdocuments.us/reader030/viewer/2022020119/5a6591dd7f8b9ac2368b45eb/html5/thumbnails/36.jpg)
1442 women with ovarian cancer • complete remission • normal CA125 levels
• platinum-based primary chemotherapy.
Underwent CA125 testing every 3 months
529 experienced a doubling in CA125 and were randomized
265 assigned to the “early treatment” group • Clinicians and patients notified of the rise in
CA125 • Treatment initiated
264 assigned to “delayed treatment” group • Clinicians and patients blinded to CA125 levels • Treatment initiated when symptoms or clinical
findings suggested recurrence
Evaluated for the length of treatment-free intervals, overall survival, and quality of life
When should treatment be initiated?
Rustin GJ,et al, Lancet 2010
2010 European study: Does earlier treatment improve survival?
![Page 37: In the Know About Recurrence, Sarah Adams, MD](https://reader030.fdocuments.us/reader030/viewer/2022020119/5a6591dd7f8b9ac2368b45eb/html5/thumbnails/37.jpg)
1442 women with ovarian cancer • complete remission • normal CA125 levels
• platinum-based primary chemotherapy.
Underwent CA125 testing every 3 months
529 experienced a doubling in CA125 and were randomized
265 assigned to the “early treatment” group • Clinicians and patients notified of the rise in
CA125 • Treatment initiated
264 assigned to “delayed treatment” group • Clinicians and patients blinded to CA125 levels • Treatment initiated when symptoms or clinical
findings suggested recurrence
Evaluated for the length of treatment-free intervals, overall survival, and quality of life
When should treatment be initiated?
Rustin GJ,et al, Lancet 2010
2010 European study: Does earlier treatment improve survival?
![Page 38: In the Know About Recurrence, Sarah Adams, MD](https://reader030.fdocuments.us/reader030/viewer/2022020119/5a6591dd7f8b9ac2368b45eb/html5/thumbnails/38.jpg)
• No difference in overall survival • Women in the early treatment group underwent more courses of chemotherapy • Delayed treatment was associated with better quality of life scores.
Rustin GJ,et al, Lancet 2010
Results:
![Page 39: In the Know About Recurrence, Sarah Adams, MD](https://reader030.fdocuments.us/reader030/viewer/2022020119/5a6591dd7f8b9ac2368b45eb/html5/thumbnails/39.jpg)
Are there benefits to enrolling in a clinical trial?
![Page 40: In the Know About Recurrence, Sarah Adams, MD](https://reader030.fdocuments.us/reader030/viewer/2022020119/5a6591dd7f8b9ac2368b45eb/html5/thumbnails/40.jpg)
Standard health care vs. clinical trials
• Standard health care: interventions designed solely to enhance the well-being of the patient that have a reasonable expectation of success
• Research (Clinical trial): an activity designed to test a hypothesis, permit conclusions to be drawn, develop or contribute to generalizable knowledge
![Page 41: In the Know About Recurrence, Sarah Adams, MD](https://reader030.fdocuments.us/reader030/viewer/2022020119/5a6591dd7f8b9ac2368b45eb/html5/thumbnails/41.jpg)
Clinical Trials
• Oversight and protection of subjects – Institutional Review Boards (IRB)
• Protect the rights and welfare of research subjects • Include members of the community
– Informed consent • Benefits, risks and discomforts • Alternatives to participation • Must be voluntary and un-coerced
• Strategies to optimize results – Randomization
• Process by which participants are assigned to treatment groups • Placebo control is optimal to evaluate new treatments
– Blinding • Single-blind: treating physician knows but patient doesn’t • Double-blind: neither the treating physician nor the patient knows
![Page 42: In the Know About Recurrence, Sarah Adams, MD](https://reader030.fdocuments.us/reader030/viewer/2022020119/5a6591dd7f8b9ac2368b45eb/html5/thumbnails/42.jpg)
Goals of clinical trials
Phase I Trials:
– Safety and tolerability
– Uncontrolled, unblinded
– Not randomized
![Page 43: In the Know About Recurrence, Sarah Adams, MD](https://reader030.fdocuments.us/reader030/viewer/2022020119/5a6591dd7f8b9ac2368b45eb/html5/thumbnails/43.jpg)
Goals of clinical trials
Phase I Trials:
– Safety and tolerability
– Uncontrolled, unblinded
– Not randomized
Phase II Trials:
– Dose finding; dose-dependent efficacy
– Controlled or uncontrolled; may be blinded or unblinded
– Randomized or not randomized
![Page 44: In the Know About Recurrence, Sarah Adams, MD](https://reader030.fdocuments.us/reader030/viewer/2022020119/5a6591dd7f8b9ac2368b45eb/html5/thumbnails/44.jpg)
Goals of clinical trials
Phase I Trials: – Safety and tolerability – Uncontrolled, unblinded – Not randomized
Phase II Trials: – Dose-finding; dose-dependent efficacy – Controlled or uncontrolled; may be blinded or unblinded – Randomized or not randomized
Phase III Trials: – therapeutic ratio (and continued safety) (Drug x compared to drug y) – Control is placebo or standard of care. – Blinded – Randomized
![Page 45: In the Know About Recurrence, Sarah Adams, MD](https://reader030.fdocuments.us/reader030/viewer/2022020119/5a6591dd7f8b9ac2368b45eb/html5/thumbnails/45.jpg)
Goals of clinical trials
Phase I Trials: – Safety and tolerability – Uncontrolled, unblinded – Not randomized
Phase II Trials: – Dose-finding; dose-dependent efficacy – Controlled or uncontrolled; may be blinded or unblinded – Randomized or not randomized
Phase III Trials: – therapeutic ratio (and continued safety) (Drug x compared to drug y) – Control is placebo or standard of care. – Blinded – Randomized
Phase IV Trials: post-marketing surveillance (safety)
![Page 46: In the Know About Recurrence, Sarah Adams, MD](https://reader030.fdocuments.us/reader030/viewer/2022020119/5a6591dd7f8b9ac2368b45eb/html5/thumbnails/46.jpg)
Benefits of clinical trials
• Additional benefits: – Oversight by a team of physicians, nurses, study personnel – both
locally and often at a national level – Expanded options for treatment – Benefit to other women with ovarian cancer by advancing our
understanding of treatment options and cancer biology
Advantages Disadvantages
Phase I trials
Access to newest therapeutic agents Dose escalation may mean that a lower dose is given to early participants
Usually not randomized or blinded Primary outcome is safety and tolerability
Smaller studies, results may be available sooner
May or may not be given with known active agents
Phase III trials
Protocol already tested in prior phase I/II with evidence of efficacy
Often randomized Often blinded
Often given with active agents; control arm is usually standard treatment
Large scale studies – may take years to learn results
![Page 47: In the Know About Recurrence, Sarah Adams, MD](https://reader030.fdocuments.us/reader030/viewer/2022020119/5a6591dd7f8b9ac2368b45eb/html5/thumbnails/47.jpg)
Questions to ask if you are considering enrolling in a clinical trial:
• What is the scientific rationale for conducting the trial? • What are the objectives of the trial? • In what phase is the trial? How many participants will there be? • What are the eligibility requirements? • What is the intervention, and what is its duration and schedule? • What are the possible risks, side effects and benefits? • What medical tests and follow-up tests will participants undergo?
How often? • What are the endpoints (measurable outcomes that indicate an
intervention’s effectiveness)? • Who is sponsoring the trial? • What is the contact information to inquire about the trial?
![Page 48: In the Know About Recurrence, Sarah Adams, MD](https://reader030.fdocuments.us/reader030/viewer/2022020119/5a6591dd7f8b9ac2368b45eb/html5/thumbnails/48.jpg)
Summary
![Page 49: In the Know About Recurrence, Sarah Adams, MD](https://reader030.fdocuments.us/reader030/viewer/2022020119/5a6591dd7f8b9ac2368b45eb/html5/thumbnails/49.jpg)
There are many options available to manage ovarian cancer recurrence
• Several factors affect choice of treatment including the presence of symptoms, response to prior treatment, availability of a clinical trial, patient preference
• Goal of treatment is to optimize quality of life and to prolong remission
• For more information about available clinical trials: www.ocrf.org/clinicaltrials
![Page 50: In the Know About Recurrence, Sarah Adams, MD](https://reader030.fdocuments.us/reader030/viewer/2022020119/5a6591dd7f8b9ac2368b45eb/html5/thumbnails/50.jpg)
Thank you – questions?
![Page 51: In the Know About Recurrence, Sarah Adams, MD](https://reader030.fdocuments.us/reader030/viewer/2022020119/5a6591dd7f8b9ac2368b45eb/html5/thumbnails/51.jpg)
Principles governing clinical trials
• Regulatory codes place the responsibility for the ethical conduct of research on the shoulders of researchers – Autonomy
• Informed consent
• Confidentiality
• Comprehension
• Voluntariness
– Beneficience • Peer review to determine whether the risks are justified
• Investigator and subject in the determination to participate
– Justice • Selection of subjects is equitable
![Page 52: In the Know About Recurrence, Sarah Adams, MD](https://reader030.fdocuments.us/reader030/viewer/2022020119/5a6591dd7f8b9ac2368b45eb/html5/thumbnails/52.jpg)
Examples of ongoing clinical trials in recurrent ovarian cancer
www.clinicaltrials.gov search: ovarian cancer, phase I
• Phase I: – Paclitaxel in combination with VS-6063 in women with advanced ovarian cancer Open-
label, multicenter, dose-escalation trial of paclitaxel in combination with VS-6063, a focal adhesion kinase inhibitor, in patients with advanced ovarian cancer. This study is comprised of 2 parts: Phase I (Dose escalation) and Phase Ib (Expansion). The purpose of this study is to assess the safety (including the recommended phase II dose), the pharmacokinetics, and the anti-cancer activity of VS-6063 when administered in combination with paclitaxel. Pharmacodynamic effects will also be examined in tumor biopsies.
• Primary outcome measures: safety, tolerability, adverse events and their frequency, duration and severity, establish the recommended phase II dose
• Secondary outcome measures: evaluate the efficacy – response rate and progression-free survival; assess pharmacokinetics
• Other outcome measures: evaluate biomarkers of VS-6063 activity; examine if tumor expression status correlates with response to VS-6063 therapy
• Phase I/II:
– Doxorubicine +BIBF 1120: to determine whether BIBF 1120 can be safely combined with Doxil and to determine the clinical activity (phase II) in women with platinum-resistant ovarian cancer
• Primary outcome measures, phase I: To find the maximum tolerated dose to be used during phase II and to evaluate the safety and toxicity of BIBF 1120 combined with Doxil
• Primary outcome measures, phase II: To assess response rate in women with recurrent ovarian cancer treated with BIBF 1120 and Doxil
• Secondary outcome measures: progression free survival; clinical rate of benefit defined by the number of patients experiencing an objective response or a CA125 resposne or sustained stable disease.
![Page 53: In the Know About Recurrence, Sarah Adams, MD](https://reader030.fdocuments.us/reader030/viewer/2022020119/5a6591dd7f8b9ac2368b45eb/html5/thumbnails/53.jpg)
• Phase III – Efficacy study of chemotherapy to treat ovarian cancer
recurrence by prolonging the platinum free interval: Liposomal Doxorubicin vs Carboplatin/Paclitaxel in patients with ovarian cancer recurrence between 6 and 12 months after previous platinum based therapy: This study will test the hypothesis that the artificial prolongation of the platinum-free interval with a non-platinum treatment will improve the effectiveness of overall therapy in patients with ovarian cancer progression occurring 6-12 months after first-line treatment with a platinum-derivative. Participants will be randomized to receive either platinum-based chemotherapy or a non-platinum drug.
• Primary outcome measures: overall survival
• Secondary outcome measures: progression free survival; changes in quality of life; number of objective responses; worst grade toxicity for each patient
• Estimated enrollment: 250
Examples of ongoing clinical trials in recurrent ovarian cancer
www.clinicaltrials.gov search: ovarian cancer, phase III